Crossover Capital Partners is a US based investment manager with a focus on healthcare investment in Asia (ex-China) and the Emerging Markets. The Crossover principals have a cumulative 90 plus years of healthcare investment experience and have managed assets across multiple strategies including long/short equity, private equity, and special situations. Crossover currently manages two separate but complimentary funds: Crossover Healthcare Emerging Asia Public Fund L.P (“Public Fund”) and Crossover Healthcare Emerging Asia Illiquid Fund LP (“Illiquid Fund”). The Public Fund is a highly liquid concentrated long/short equity fund with a Pan Asia (ex-China) and Emerging Markets geographical focus. The Illiquid Fund combines private equity, less liquid small capitalization public markets opportunities, and structured direct investments. The two Funds are separate vehicles and structured to give clients the choice of allocating to the Public Fund, the Illiquid Fund, or both. All of Crossover’s investments are made in consideration of environmental, social, and government impacts.